Agilent Technologies opened a Dissolution Center of Excellence in Craven Arms, United Kingdom, on Oct. 12, 2022.
Agilent Technologies opened a Dissolution Center of Excellence in Craven Arms, United Kingdom, on Oct. 12, 2022, consolidating all of the company’s activities in the area of dissolution under one roof.
According to a company press release, the modernized facility will house the company’s core dissolution business, which includes R&D, quality, support, applications, marketing, and other segments. Additionally, the dissolution center will be a hub for Agilent’s global dissolution customers where they will be able to access a variety of tools, such as education, training, application development, and both on-site and virtual demonstrations.
“The growth in our dissolution business has really driven the need for this larger facility,” said Steve O’Donohue, director at the Craven Arms site, in the press release. “Our new flagship site will enable us to develop a truly unified approach to dissolution for the future. The location will also facilitate greater innovation and manufacturing capabilities to support Agilent’s digital lab initiatives.”
“By centering all dissolution activities in the UK, customers from all time zones will have improved access to our team of experts, with the latest technology to virtually connect for education, training, troubleshooting, and all other types of dissolution testing assistance,” added Dan Spisak, dissolution marketing manager at Agilent, in the press release.
Source: Agilent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.